Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Biomarkers Market Be Worth By 2029?

In recent years, the biomarkers market has experienced significant growth. The market is projected to expand from $68.77 billion in 2024 to $77.42 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. The historical growth of this market is credited to developments in genomics and proteomics technologies, rising chronic disease occurrences, increased focus on personalized medicine, a surge in companion diagnostics demand, and wider application in drug development.

The biomarkers market is anticipated to experience accelerated expansion in the forthcoming years, surging to $131.78 billion by 2029 with a compound annual growth rate (CAGR) of 14.2%. This surge over the forecast period can be credited to the amplified focus on early detection and prevention of diseases, the widening application of biomarkers in oncology and immunotherapy, increased funding for precision medicine campaigns, the emerging prominence of liquid biopsy as a non-invasive method for detecting biomarkers, and the rising preference for biomarkers in the discovery and development of drugs. The forecast period is also expected to see significant trends such as the creation of multi-biomarker panels, the emergence of exosome-based biomarkers, the incorporation of real-world data into biomarker research, the increased adoption of point-of-care biomarker testing, and the exploration of microbiome-based biomarkers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Market Forces Are Contributing To The Growth Of The Biomarkers Market?

The surge in cardiac ailments is predicted to fuel the expansion of the biomarkers market throughout the projected period. In recent years, the application of biomarkers in treating patients with heart conditions has seen a significant rise. At present, natriuretic peptides are the most commonly utilized biomarkers, aiding in the detection of heart failure in patients. Additionally, biomarkers like circulating biomarkers with a high sensitivity C-reactive protein are employed in diagnosing heart failure. Notably, heart disease is the primary cause of mortality across most racial and ethnic groups within the United States, with the rising cardiac disease prevalence catalyzing the demand for biomarkers. For example, a report issued by the American College of Cardiology, a non-profit medical association in the U.S., in August 2022 suggests that all four cardiovascular risk factors will witness an upswing between 2025 and 2060 in the United States. The most significant escalation is predicted in diabetes, with a hike of 39.3% escalating to 55 million individuals, trailed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The report also noted the highest anticipated increases in the rate of cardiovascular diseases would occur in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attacks (16.9% to 16 million). Consequently, the surge in heart diseases and related fatalities will trigger a growth spurt in the biomarkers market.

Which Segments Define The Structure Of The Biomarkers Market?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

What Strategic Shifts And Innovations Are Influencing The Biomarkers Market?

Leading firms in the biomarker sector are concentrating on creating novel solutions such as pioneering biological indicators to boost innovation through joint research, technology assimilation and strong clinical confirmation. A pioneering biological indicator is a newly discovered marker that mirrors biological reactions and is helpful in diagnosing or observing diseases. This can be a molecule, gene, or cellular attribute with potential benefits for personalized medicine. For instance, Genialis, a US-based computational precision medicine firm, introduced a first-of-its-kind biomarker in September 2024. This first-in-class biomarker improves the predictive accuracy for responses of patients to KRAS inhibitors, facilitating tailored treatment options and enhancing clinical results. Its wide-ranging use across different types of cancer aids efficient drug evolution and refines the selection of patients for targeted treatments.

Which Firms Are Making The Biggest Impact In The Biomarkers Market?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Is Forecasted To Lead The Biomarkers Market In The Coming Years?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model